When can RCTs and observational intervention studies mislead us and what can we do about it?

International Journal of Clinical Practice

Volumn 63, Issue 11, 2009, Pages 1562-1564

  Rosen M ^a   Axelsson, S ^a   Lindblom, J ^a  

^a Swedish Council on Technology Assessment in Health Care   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG RESEARCH; HUMAN; INTERVENTION STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; INTERVENTION STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 70349959995     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02202.x     Document Type: Review

References (20)

1. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. NEJM 2000 342 : 1887 1892.
2. Benson K, Hartz AJ. A comparison of observational studies and randomized controlled trials. NEJM 2000 342 : 1878 1886.
3. Kunz R, Vist GE., Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007, Issue 2. Art. No.: MR000012. DOI :.
4. Vandenbroucke JP. The HRT controversy: observational studies and RCTs fall in line. Lancet 2009 373 : 1233 1235.
5. Lawlor DA, Davey Smith G, Ebrahim S. Socioeconomic position and hormone replacement therapy use: explaining the discrepancy in evidence from observational and randomized controlled trials. Am J Public Health 2004 94 : 2149 2154.
6. Lawlor DA, Davey Smith G, Brucksdorfer KR, Kundu D, Ebrahim S. Those confounded vitamins: what can we learn from the differences bbetween observational versus randomised trial evidence? Lancet 2004 363 : 1724 1727.
7. Commission on Social Determinants of Health. CSDH Final Report: Closing the Gap in a Generation: Health Equity Through Action on the Social Determinants of Health. Geneva : World Health Organisation, 2008.
8. Ringbäck Weitoft G, Rosén M, Ericsson Ö, Ljung R. Education and drug use in Sweden - a nationwide register-based study. Pharmacoepidemiol Drug Saf 2008 17 : 1020 1028.
9. Haglund B, Köster M, Rosén M. Inequality in access to coronary revascularisation in Sweden. Scand Cardivasc J 2004 38 : 334 339.
10. Rosén M, Axelsson S, Lindblom J. Observational studies versus RCTs: what about socioeconomic factors? Lancet 2009 373 : 2026.
11. von Elm E, Egger M, Altman DG, Pocock SJ, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007 335 : 806 808. (Pubitemid 350057266)
12. Reeves BC, Deeks JJ, Higgins JPT, Wells GA. Chapter 13: Including non-randomized studies. In : Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK : John Wiley & Sons, 2008 : 391 432.
13. Fergusson DA, Hebert PC, Mazer CD et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008 358 : 2319 2331.
14. Henry DA, Carless PA, Moxey AJ et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007, Issue 4. Art. No.: CD001886. DOI :.
15. Levi M, Cromheecke ME, de Jonge E et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999 354 : 1940 1947.
16. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004 128 : 442 448.
17. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 : 353 365.
18. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 2008 358 : 771 783.
19. Shaw AD, Stafford-Smith M, White WD et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008 358 : 784 793.
20. Rosén M. The aprotinin saga and the risks of conducting meta-analyses on small randomised controlled trials - a critique of a Cochrane review. BMC Health Serv Res 2009 9 : 34. doi :.